BRPI0510419B8 - comprimido revestido e método para preparar um comprimido revestido. - Google Patents

comprimido revestido e método para preparar um comprimido revestido.

Info

Publication number
BRPI0510419B8
BRPI0510419B8 BRPI0510419A BRPI0510419A BRPI0510419B8 BR PI0510419 B8 BRPI0510419 B8 BR PI0510419B8 BR PI0510419 A BRPI0510419 A BR PI0510419A BR PI0510419 A BRPI0510419 A BR PI0510419A BR PI0510419 B8 BRPI0510419 B8 BR PI0510419B8
Authority
BR
Brazil
Prior art keywords
coated tablet
layer
coating
tablet
making
Prior art date
Application number
BRPI0510419A
Other languages
English (en)
Inventor
V Li Bing
Desai Divyakant
Original Assignee
Astrazeneca Ab
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34971747&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0510419(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab, Bristol Myers Squibb Co filed Critical Astrazeneca Ab
Publication of BRPI0510419A publication Critical patent/BRPI0510419A/pt
Publication of BRPI0510419B1 publication Critical patent/BRPI0510419B1/pt
Publication of BRPI0510419B8 publication Critical patent/BRPI0510419B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

comprimido revestido e método para preparar um comprimido revestido. a presente invenção refere-se a uma formulação de comprimido revestido que inclui um medicamento tal como o inibidor dpp4, saxaglipitin ou seu sal hci, que é sujeito à ciclização intramolecular, cuja formulação inclui um núcleo de comprimido contendo um ou mais agentes de enchimento, e outros excipientes convencionais, cujo núcleo do comprimido inclui um revestimento no mesmo que pode incluir duas ou mais camadas, cuja, pelo menos uma, camada é uma camada de revestimento de vedação interna que é formada de um ou mais polímeros de revestimento, cuja segunda camada é formada de medicamento que é o inibidor dpp4 e um ou mais polímeros de revestimento, e uma opcional, mas preferível terceira camada protetora externa que é formada de um ou mais polímeros de revestimento. método para formação do comprimido revestido é também provido.
BRPI0510419A 2004-05-28 2005-05-26 comprimido revestido e método para preparar um comprimido revestido. BRPI0510419B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57531904P 2004-05-28 2004-05-28
US60/575,319 2004-05-28
PCT/US2005/018692 WO2005117841A1 (en) 2004-05-28 2005-05-26 Coated tablet formulation and method

Publications (3)

Publication Number Publication Date
BRPI0510419A BRPI0510419A (pt) 2007-10-30
BRPI0510419B1 BRPI0510419B1 (pt) 2019-04-09
BRPI0510419B8 true BRPI0510419B8 (pt) 2021-05-25

Family

ID=34971747

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510419A BRPI0510419B8 (pt) 2004-05-28 2005-05-26 comprimido revestido e método para preparar um comprimido revestido.

Country Status (33)

Country Link
US (4) US7951400B2 (pt)
EP (3) EP2298288B2 (pt)
JP (1) JP4901727B2 (pt)
KR (2) KR20120064141A (pt)
CN (2) CN102895208B (pt)
AR (2) AR049062A1 (pt)
AU (1) AU2005249467B2 (pt)
BR (1) BRPI0510419B8 (pt)
CA (1) CA2568391C (pt)
CY (2) CY1117813T1 (pt)
DK (2) DK2298288T4 (pt)
ES (3) ES2593582T5 (pt)
GE (1) GEP20094639B (pt)
HR (2) HRP20160880T4 (pt)
HU (2) HUE029446T2 (pt)
IL (2) IL179454A (pt)
LT (1) LT2298288T (pt)
ME (2) ME02643B (pt)
MX (1) MXPA06013711A (pt)
MY (1) MY147639A (pt)
NO (1) NO343907B1 (pt)
NZ (1) NZ551591A (pt)
PE (1) PE20060425A1 (pt)
PH (1) PH12013500450A1 (pt)
PL (2) PL2298288T5 (pt)
PT (2) PT2298288T (pt)
RS (2) RS54929B2 (pt)
RU (1) RU2372894C2 (pt)
SI (3) SI1753406T2 (pt)
TW (2) TWI415635B (pt)
UA (1) UA88168C2 (pt)
WO (1) WO2005117841A1 (pt)
ZA (1) ZA200609541B (pt)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0487425A (ja) * 1990-07-31 1992-03-19 Fujitsu Ltd 回線切り替え装置
EE05643B1 (et) * 2001-02-24 2013-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ksantiini derivaadid, nende valmistamine ja kasutamine ravimina
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
ATE537141T1 (de) 2004-02-05 2011-12-15 Kyorin Seiyaku Kk Bicycloesterderivat
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
TW200534879A (en) * 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
US20050256314A1 (en) * 2004-05-04 2005-11-17 Soojin Kim Process employing controlled crystallization in forming crystals of a pharmaceutical
US7829720B2 (en) * 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
TWI415635B (zh) 2004-05-28 2013-11-21 必治妥施貴寶公司 加衣錠片調製物及製備彼之方法
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
GB0526291D0 (en) * 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
CA2635841A1 (en) * 2006-02-09 2007-08-16 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical formulations of montelukast sodium
AU2007224066B2 (en) * 2006-03-08 2011-10-27 Kyorin Pharmaceutical Co., Ltd. Method for producing aminoacetylpyrrolidinecarbonitrile derivative and production intermediate thereof
CN102838599A (zh) 2006-05-04 2012-12-26 贝林格尔.英格海姆国际有限公司 多晶型
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) * 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
US20070172525A1 (en) * 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations
US20080064701A1 (en) * 2007-04-24 2008-03-13 Ramesh Sesha Anti-diabetic combinations
AR065809A1 (es) 2007-03-22 2009-07-01 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
ATE550319T1 (de) * 2007-03-22 2012-04-15 Kyorin Seiyaku Kk Verfahren zur herstellung eines aminoacetylpyrrolidincarbonitrilderivats
PE20090696A1 (es) 2007-04-20 2009-06-20 Bristol Myers Squibb Co Formas cristalinas de saxagliptina y procesos para preparar las mismas
ES2359770T3 (es) * 2007-06-22 2011-05-26 Bristol-Myers Squibb Company Composiciones en comprimidos que contienen atazanavir.
JP2010530892A (ja) * 2007-06-22 2010-09-16 ブリストル−マイヤーズ スクイブ カンパニー アタザナビルを含む錠剤組成物
SI2170292T1 (sl) * 2007-06-22 2014-05-30 Bristol-Myers Squibb Holdings Ireland Tabletirani sestavki, ki vsebujejo atazanavir
JP2010530889A (ja) * 2007-06-22 2010-09-16 ブリストル−マイヤーズ スクイブ カンパニー アタザナビルを含む錠剤組成物
JP5623275B2 (ja) * 2007-07-31 2014-11-12 カーギル インコーポレイテッド 直接打錠可能なデキストロース
CA2923102C (en) * 2007-08-13 2019-10-15 Omeho Life Sciences Inc. Abuse resistant drugs, method of use and method of making
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
US8551524B2 (en) * 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
IT1393244B1 (it) * 2008-07-18 2012-04-12 Universita' Degli Studi Di Milano Sistema per il rilascio al colon di farmaci suscettibili di degradazione enzimatica e/o scarsamente assorbiti nel tratto gastrointestinale
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
CN102119139A (zh) * 2008-08-07 2011-07-06 杏林制药株式会社 二环[2.2.2]辛胺衍生物的制造方法
AU2009282376A1 (en) * 2008-08-12 2010-02-18 Inspirion Delivery Technologies, Llc Pharmaceutical compositions configured to deter dosage form splitting
EP2327406A4 (en) * 2008-08-14 2014-04-09 Kyorin Seiyaku Kk STABILIZED PHARMACEUTICAL COMPOSITION
MX370599B (es) 2008-08-15 2019-12-18 Boehringer Ingelheim Int Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab.
BRPI0919288A2 (pt) 2008-09-10 2015-12-15 Boehring Ingelheim Internat Gmbh teriapia de combinação para tratamento de diabetes e condições relacionadas.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
DE102008059206A1 (de) 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
EA022310B1 (ru) 2008-12-23 2015-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Солевые формы органического соединения
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
TWI466672B (zh) 2009-01-29 2015-01-01 Boehringer Ingelheim Int 小兒科病人糖尿病之治療
PL2395983T3 (pl) 2009-02-13 2020-09-07 Boehringer Ingelheim International Gmbh Kompozycja farmaceutyczna zawierająca inhibitor sglt2, inhibitor dpp-iv i ewentualnie dalszy środek przeciwcukrzycowy oraz jej zastosowania
NZ619520A (en) 2009-02-13 2015-06-26 Boehringer Ingelheim Int Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
US20120029032A1 (en) 2009-03-27 2012-02-02 Kyorin Pharmaceutical Co., Ltd. Matrix-type sustained release preparation containing basic additive
SG174504A1 (en) 2009-03-27 2011-10-28 Bristol Myers Squibb Co Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors
AU2010233718B2 (en) 2009-04-09 2015-11-05 Sandoz Ag Crystal forms of Saxagliptin
ES2689107T3 (es) 2009-11-13 2018-11-08 Astrazeneca Ab Formulaciones de tabletas bicapa
CN104825417A (zh) 2009-11-13 2015-08-12 阿斯利康(瑞典)有限公司 立即释放片剂
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
EP2547339A1 (en) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
CN102210693B (zh) * 2010-04-10 2013-10-09 山东新华制药股份有限公司 一种阿司匹林和双嘧达莫多层片的制备方法
EA201291169A1 (ru) 2010-05-05 2013-04-30 Ассия Кемикал Индастриз Лтд. Промежуточные соединения саксаглиптина, полиморфы саксаглиптина и способы их получения
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
EP2601175A1 (en) 2010-08-06 2013-06-12 Sandoz AG A novel crystalline compound comprising saxagliptin and phosphoric acid
WO2012017029A1 (en) 2010-08-06 2012-02-09 Sandoz Ag Novel salts of saxagrliptin with organic di-acids
AU2011295837B2 (en) 2010-09-03 2015-06-18 Astrazeneca Uk Limited Drug formulations using water soluble antioxidants
US8410288B2 (en) 2010-10-04 2013-04-02 Teva Pharmaceutical Industries Ltd. Polymorphs of Saxagliptin hydrochloride and processes for preparing them
ES2586931T3 (es) 2010-11-04 2016-10-19 Albireo Ab Inhibidores de IBAT para el tratamiento de enfermedades hepáticas
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CN102086172A (zh) * 2011-01-13 2011-06-08 廖国超 沙格列汀的药用盐及其制备方法
EP2670397B1 (en) * 2011-02-01 2020-05-13 Bristol-Myers Squibb Company Pharmaceutical formulations including an amine compound
CA2841552C (en) 2011-07-15 2020-06-23 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
AR089646A1 (es) 2011-08-12 2014-09-10 Boehringer Ingelheim Vetmed Inhibidores de corrientes funny (if) para utilizar en un metodo de tratamiento y prevencion de la insuficiencia cardiaca en felinos
EP2753328A1 (en) 2011-09-07 2014-07-16 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dpp-iv inhibitor formulations
US9446000B2 (en) 2011-09-08 2016-09-20 Masdar Institute Of Science And Technology Cellulosic gel material as a pharmaceutical excipient
PL2578208T3 (pl) 2011-10-06 2014-10-31 Sanovel Ilac Sanayi Ve Ticaret As Stałe formulacje dawkowane inhibitora DPP-IV
WO2013106526A1 (en) 2012-01-10 2013-07-18 Teva Pharmaceutical Industries Ltd. Saxagliptin parmaceutical formulations
WO2013130785A2 (en) 2012-03-01 2013-09-06 Bristol-Myers Squibb Company Extended release pharmaceutical formulations of water-soluble active pharmaceutical ingredients and methods for making the same
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6231553B2 (ja) 2012-05-07 2017-11-15 バイエル ファーマ アクチエンゲゼルシャフト ニフェジピンおよびカンデサルタン・シレキセチルを含む医薬投与形を製造する方法
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2013179307A2 (en) * 2012-05-29 2013-12-05 Mylan Laboratories Limited Stabilized pharmaceutical compositions of saxagliptin
WO2014030051A1 (en) 2012-08-23 2014-02-27 Aurobindo Pharma Limited Stable pharmaceutical compositions comprising saxagliptin
JP6283316B2 (ja) * 2012-10-26 2018-02-21 株式会社三和化学研究所 アナグリプチン含有固形製剤
WO2014096983A1 (en) 2012-12-21 2014-06-26 Wockhardt Limited Stable pharmaceutical compositions of saxagliptin or salts thereof
US20150250734A1 (en) * 2012-12-21 2015-09-10 Wockhardt Limited Stable pharmaceutical compositions of saxagliptin or salts thereof
WO2014146093A2 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
WO2014193528A1 (en) * 2013-04-29 2014-12-04 Anovel Pharmaceuticals, Llc Amorphous dosage forms and methods
CN103316056B (zh) * 2013-06-24 2015-07-08 江苏鹏鹞药业有限公司 一种板蓝根包衣分散片及其制备方法
WO2015071887A1 (en) 2013-11-18 2015-05-21 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of saxagliptin
WO2015071889A1 (en) 2013-11-18 2015-05-21 Ranbaxy Laboratories Limited Oral compositions of saxagliptin
EP3096891B1 (en) 2014-01-21 2020-04-08 BPSI Holdings, LLC. Immediate release film coatings containing medium chain glycerides and substrates coated therewith
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
CN106659726A (zh) * 2014-06-25 2017-05-10 Ea制药株式会社 固体制剂及其着色防止或着色减少方法
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
CN105520913B (zh) * 2014-09-28 2020-06-23 石药集团中奇制药技术（石家庄）有限公司 一种包含沙格列汀的微丸、其用途及其制备方法
CN105497023B (zh) * 2014-10-15 2021-05-25 北京福元医药股份有限公司 一种沙格列汀药物制剂
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
CN104557943B (zh) * 2014-12-23 2017-05-03 扬子江药业集团四川海蓉药业有限公司 一种维格列汀杂质的制备方法
CN105796503B (zh) * 2014-12-30 2019-05-07 深圳翰宇药业股份有限公司 一种沙格列汀微丸及其制剂
CN104672243B (zh) * 2015-02-10 2017-09-22 华润赛科药业有限责任公司 维格列汀降解杂质的制备方法
HRP20200432T1 (hr) 2015-04-02 2020-06-12 Theravance Biopharma R&D Ip, Llc Oblik za kombinacijsko doziranje antagonista mu opioidnog receptora i opioidnog sredstva
CN106176661B (zh) * 2015-04-29 2019-02-01 四川科伦药物研究院有限公司 一种沙格列汀或其盐的胶囊及其制备方法
IL256299B2 (en) * 2015-06-30 2023-11-01 Genentech Inc Immediate-release tablets containing a drug and processes for creating the tablets
CN106924207A (zh) * 2015-12-31 2017-07-07 深圳翰宇药业股份有限公司 一种维格列汀片剂及其制备方法
EP3413878B1 (en) 2016-02-09 2021-04-14 Albireo AB Oral cholestyramine formulation and use thereof
EP3413877B1 (en) 2016-02-09 2021-04-07 Albireo AB Oral cholestyramine formulation and use thereof
EP3413875B1 (en) 2016-02-09 2020-01-29 Albireo AB Cholestyramine pellets and methods for preparation thereof
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
JP2020530448A (ja) 2017-08-09 2020-10-22 アルビレオ・アクチボラグ コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用
CN108822820B (zh) * 2018-05-22 2020-11-03 东莞理工学院 一种隔离型水合物动力学抑制胶囊及其制备方法与应用
JP7391048B2 (ja) 2018-06-05 2023-12-04 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
MX2020013839A (es) 2018-06-20 2021-03-25 Albireo Ab Formulacion farmaceutica de odevixibat.
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
WO2020098904A1 (en) 2018-11-12 2020-05-22 Pharmaceutical Oriented Services Ltd Dosage form containing metformin and a dipeptidyl peptidase iv inhibitor
TWI835997B (zh) 2019-02-06 2024-03-21 瑞典商艾爾比瑞歐公司 苯并噻氮呯化合物及其用作膽酸調節劑之用途
RS63899B1 (sr) 2019-02-06 2023-02-28 Albireo Ab Benzotiadiazepinska jedinjenja i njihova upotreba kao modulatora žučnih kiselina
CN109999006A (zh) * 2019-04-28 2019-07-12 江苏豪森药业集团有限公司 沙格列汀包衣片及其制备方法
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
JP7665620B2 (ja) 2019-12-04 2025-04-21 アルビレオ・アクチボラグ ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
CA3158181A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
EP4069359B1 (en) 2019-12-04 2024-01-03 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
BR112022010505A2 (pt) 2019-12-04 2022-09-06 Albireo Ab Compostos de benzotia(di)azepina e seu uso como moduladores do ácido biliar
JP7514121B2 (ja) 2020-06-23 2024-07-10 沢井製薬株式会社 サキサグリプチン含有製剤及びその製造方法
CA3186857A1 (en) 2020-08-03 2022-02-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
AU2021379076A1 (en) 2020-11-12 2023-06-08 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
AU2021390172A1 (en) 2020-12-04 2023-06-22 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
JP2022135147A (ja) * 2021-03-04 2022-09-15 日医工株式会社 サキサグリプチン含有錠剤
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
KR20220165346A (ko) 2021-06-08 2022-12-15 동아에스티 주식회사 에보글립틴의 안정성이 개선된 제제

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3696188A (en) * 1971-06-16 1972-10-03 Schering Corp Laminated tablets
DE3403329A1 (de) * 1984-02-01 1985-08-01 Horst Dr. 4019 Monheim Zerbe Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe
JPS6186211A (ja) 1984-10-04 1986-05-01 日本碍子株式会社 セラミックス複合構造体及びその製造法
FR2623810B2 (fr) 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
US5158777A (en) 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
CA2068402C (en) 1991-06-14 1998-09-22 Michael R. Hoy Taste mask coatings for preparation of chewable pharmaceutical tablets
US5428048A (en) 1993-11-08 1995-06-27 American Home Products Corporation Aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and anto-arteriosclerotic agents
GB9407386D0 (en) 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
TW483763B (en) * 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
TW522014B (en) 1997-02-07 2003-03-01 Sepracor Inc Lactose-free, non-hygroscopic and anhydrous pharmaceutical unit dosage form containing descarboethoxyloratadine
GB9715896D0 (en) 1997-07-28 1997-10-01 Sca Packaging Ltd Containers
US6087383A (en) 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
US6322819B1 (en) * 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
CA2368023A1 (en) 1999-03-22 2000-09-28 Guixue Yu Fused pyridopyridazine inhibitors of cgmp phosphodiesterase
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
WO2001034148A1 (en) 1999-11-11 2001-05-17 Kyorin Pharmaceutical Co., Ltd. Solid preparations for oral use
US6569456B2 (en) * 2000-01-13 2003-05-27 Osmotica Corp. Osmotic device containing diltiazem and an ACE inhibitor or diuretic
DK1248604T4 (da) * 2000-01-21 2012-05-21 Novartis Ag Kombinationer indeholdende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler
US6254888B1 (en) 2000-01-28 2001-07-03 Boehringer Ingelheim Pharmaceuticals, Inc. Method for coating pharmaceutical dosage forms
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
IL145106A0 (en) 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
US6670344B2 (en) 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
US6670334B2 (en) 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
WO2002085335A1 (en) 2001-04-18 2002-10-31 Nostrum Pharmaceuticals Inc. A novel coating for a sustained release pharmaceutical composition
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
EP1467717A1 (en) 2002-01-15 2004-10-20 Ranbaxy Laboratories Limited Stable pharmaceutical compositions comprising ace inhibitor(s)
KR100456833B1 (ko) 2002-08-01 2004-11-10 주식회사 대웅 아목시실린 및 클라불라네이트를 함유하는 유핵정
US7670624B2 (en) 2004-01-29 2010-03-02 Astella Pharma Inc. Gastrointestinal-specific multiple drug release system
TW200534879A (en) 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
US7829720B2 (en) 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
US20050256314A1 (en) 2004-05-04 2005-11-17 Soojin Kim Process employing controlled crystallization in forming crystals of a pharmaceutical
US20050288343A1 (en) 2004-05-19 2005-12-29 Andrew Rusowicz Process of preparing substituted carbamates and intermediates thereof
TWI415635B (zh) † 2004-05-28 2013-11-21 必治妥施貴寶公司 加衣錠片調製物及製備彼之方法

Also Published As

Publication number Publication date
SI2298288T1 (sl) 2016-11-30
KR101290925B1 (ko) 2013-07-29
ES2582646T5 (es) 2020-03-30
UA88168C2 (uk) 2009-09-25
JP2008501025A (ja) 2008-01-17
HRP20161210T4 (hr) 2019-08-09
LT2298288T (lt) 2016-11-10
CA2568391C (en) 2013-05-14
HUE029446T2 (en) 2017-03-28
HK1155399A1 (en) 2012-05-18
EP2298288B2 (en) 2019-04-03
RS55174B2 (sr) 2019-07-31
BRPI0510419A (pt) 2007-10-30
EP3078369A1 (en) 2016-10-12
RS54929B2 (sr) 2019-11-29
ZA200609541B (en) 2008-01-08
HK1094951A1 (zh) 2007-04-20
US20140255486A1 (en) 2014-09-11
DK1753406T4 (da) 2019-11-04
HUE029039T2 (en) 2017-01-30
US8628799B2 (en) 2014-01-14
JP4901727B2 (ja) 2012-03-21
PT2298288T (pt) 2016-09-28
PL1753406T5 (pl) 2019-12-31
AR099567A2 (es) 2016-08-03
US7951400B2 (en) 2011-05-31
IL179454A0 (en) 2007-05-15
PL2298288T5 (pl) 2019-08-30
RS54929B1 (sr) 2016-10-31
US20050266080A1 (en) 2005-12-01
AU2005249467A1 (en) 2005-12-15
KR20120064141A (ko) 2012-06-18
GEP20094639B (en) 2009-03-10
BRPI0510419B1 (pt) 2019-04-09
EP3078369B1 (en) 2019-08-21
HRP20160880T1 (hr) 2016-09-23
PE20060425A1 (es) 2006-06-01
CN102895208A (zh) 2013-01-30
RU2006146971A (ru) 2008-07-20
TW200609002A (en) 2006-03-16
AR049062A1 (es) 2006-06-21
CN1988891B (zh) 2012-11-28
AU2005249467B2 (en) 2010-10-21
KR20070027560A (ko) 2007-03-09
SI1753406T2 (sl) 2019-12-31
TW201204414A (en) 2012-02-01
WO2005117841A1 (en) 2005-12-15
RU2372894C2 (ru) 2009-11-20
PH12013500450A1 (en) 2013-09-02
ES2593582T3 (es) 2016-12-09
IL218117A (en) 2017-09-28
SI1753406T1 (sl) 2016-08-31
NO343907B1 (no) 2019-07-01
NO20065870L (no) 2006-12-22
US9339472B2 (en) 2016-05-17
IL218117A0 (en) 2012-03-29
PL1753406T3 (pl) 2016-10-31
ES2582646T3 (es) 2016-09-14
EP1753406B1 (en) 2016-04-20
NZ551591A (en) 2010-03-26
US20110200672A1 (en) 2011-08-18
DK2298288T4 (da) 2019-05-27
CY1117813T1 (el) 2017-05-17
RS55174B1 (sr) 2017-01-31
TWI415635B (zh) 2013-11-21
ME02516B (me) 2017-02-20
MY147639A (en) 2012-12-31
EP2298288B1 (en) 2016-06-22
IL179454A (en) 2012-03-29
US20140120163A1 (en) 2014-05-01
EP1753406A1 (en) 2007-02-21
ME02643B (me) 2017-06-20
EP2298288A1 (en) 2011-03-23
CN102895208B (zh) 2015-05-13
SI2298288T2 (sl) 2019-06-28
EP1753406B2 (en) 2019-08-21
CA2568391A1 (en) 2005-12-15
ES2754573T3 (es) 2020-04-20
MXPA06013711A (es) 2007-02-13
TWI354569B (en) 2011-12-21
HRP20160880T4 (hr) 2020-01-10
CN1988891A (zh) 2007-06-27
CY1118162T1 (el) 2017-06-28
ES2593582T5 (es) 2019-10-22
PT1753406E (pt) 2016-06-17
PL2298288T3 (pl) 2016-12-30
HRP20161210T1 (hr) 2016-11-18
DK2298288T3 (en) 2016-10-03

Similar Documents

Publication Publication Date Title
BRPI0510419A (pt) formulação e método de comprimido revestido
BR112021018847A2 (pt) Composições de pélete, método para preparar uma composição de pélete, formulação oral de inibidor de parp, método para tratar uma doença associada à parp
PT3883579T (pt) Terapia de combinação incluindo um inibidor de kras-g12c e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cancros
BR112013024585A8 (pt) formas de dosagem farmacêutica de liberação controlada
BRPI1011838B8 (pt) compostos de carboxamida heterocíclica de diamino, seu uso, composição farmacêutica que os compreende e inibidor contra a atividade de cinase de proteína de fusão eml4-alk
SV2009003307A (es) Quinazolinas para la inhibicion de pdk1
BR112012001353B8 (pt) anel vaginal, e, método para fabricar um anel vaginal
BRPI0513089A (pt) composição de liberação de drogas controlada demonstrando um padrão de liberação de ordem ascendente de zero e métodos de fabricação de tal composição
PT2040755E (pt) Combinação de um inibidor de colinesterase e um composto com afinidade para o receptor 5-ht6
BRPI0513909A (pt) comprimido farmacêutico de camada múltipla para a liberação controlada de ingredientes ativos com solubilidade altamente dependente do ph
CY1110658T1 (el) Χρηση του καρραγηνου για τη θεραπεια μολυνσεων απο ρινοϊο
MX2020003593A (es) Compuestos de benzotiazol y metodos para usar los mismos para tratar trastornos neurodegenerativos.
ECSP088619A (es) Combinación de un inhibidor de acetilcolinesterasa y un antagonista de 5-ht6 para el tratamiento de la disfunción cognitiva
CR20220251A (es) Nuevos derivados de metilquinazolinona
BR112016001822A2 (pt) comprimido farmacêutico compreendendo ácido acetilsalicílico e clopidogrel
BR112021022255A2 (pt) Composto usado como inibidor de quinase e aplicação do mesmo
BRPI0415053A (pt) inibidor de p-glicoproteìna, método para preparar o mesmo e composição farmacêutica que compreende o mesmo
CL2021002480A1 (es) Agonistas compuestos macrocíclicos como de sting
MX2019003373A (es) Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos.
PH12019500849A1 (en) Naphthyridinone derivatives and their use inthe treatment of arrhythmia
BR112021015744A2 (pt) Combinações de compostos de beta-lactama e probenecida e seu uso
AR047922A1 (es) Nuevos derivados de pentafluorsulfanilo, su obtencion y su utilizacion como agentes farmaceuticos
BRPI0606322A2 (pt) formulações intravenosas de inibidores de pde-5
ECSP22002699A (es) Cápsula de tipo desintegración retardada y método para producir la misma
NO20073023L (no) Forhindring av vertikal endoparasitt infeksjoner

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ASTRAZENECA AB (SE)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/04/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/05/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.